Bioventus (BVS) Liabilities from Discontinued Operations (2022)

Bioventus' (BVS) quarterly Liabilities from Discontinued Operations came in at 119087000.0 in Q4 2022.

Bioventus (BVS) Liabilities from Discontinued Operations (2022) Analysis & Trends

Bioventus (BVS) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 119087000.0 in Q4 2022.

Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 119087000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 119087000.0 (changed N/A YoY) and the FY2022 annual result came in at 119087000.0, changed N/A from the prior year.
Liabilities from Discontinued Operations was little changed at 119087000.0 in Q4 2022.
In the past five years, Liabilities from Discontinued Operations ranged from a high of 119087000.0 in Q4 2022 to a low of 119087000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Bioventus	972.56 Mn	943.11 Mn	105.67 Mn

Download Data

Date	Value
Dec 31, 2022	119.09 Mn
Dec 31, 2022	119.09 Mn